Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01373216 | Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass | PHASE3 | COMPLETED | 38 | — | — | Jun 1, 2011 | Dec 1, 2014 | Feb 2, 2016 | 1 | Czechia |
* cardiac chamber dimensions * left ventricular systolic function * left ventricular diastolic function * right ventricular systolic function
| Arm | Type | Description |
|---|---|---|
| Exenatide | EXPERIMENTAL | Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment |
| Control | NO_INTERVENTION | Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment |
| Name | Type | Description |
|---|---|---|
| Exenatide | DRUG | Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours |
Inclusion Criteria: * elective coronary artery bypass grafting operation (CABG) * decreased left ventricular (LV) systolic function (EF LV ≤ 50%) * Age 18 to 85 * Signed informed consent * Females with childbearing potential have to use appropriate contraceptive measures during the whole study peri...